NCT06109207 2024-07-23
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
West China Hospital
Phase 1 Recruiting
Clinical Trials
3 trialsNCT06225921 2024-03-06
Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
West China Hospital
Phase 1 Recruiting
NCT05586841 2022-10-19
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â… b Study
Beijing 302 Hospital
Phase 1 Unknown